All Articles

The American Cancer Society acknowledged an estimated 1,688,780 new cancer diagnoses by the end of 2017.

Work is central for most adults in the United States, including women with breast cancer.

Cancer patients must juggle doctor appointments; combat treatment side effects, while trying to maintain a sense of normalcy; and handle financial struggles.

The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.

This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps.

Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease).

Of the 1.6 million individuals annually diagnosed with cancer, 522,166 received chemoradation, with 234,975 developing toxic mucositis and 20% dying within 5 years due largely to mucositis-mediated unplanned treatment breaks.

Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.

Symptoms that patients with cancer experience, either due to their illness or as a result of cancer treatment, are known to diminish their health-related quality of life.

Significantly improved outcomes with D+T vs BRAF inhibitor (BRAFi) monotherapy have been demonstrated in phase 3 BRAF V600E/K–mutant melanoma trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]), supporting use of D+T as a treatment for this disease.